Taking phototherapeutics from concept to clinical launch.

Loading...
Thumbnail Image

Date

2021-01

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

24
views
18
downloads

Citation Stats

Abstract

More than four decades have passed since the first example of a light-activated (caged) compound was described. In the intervening years, a large number of light-responsive derivatives have been reported, several of which have found utility under a variety of in vitro conditions using cells and tissues. Light-triggered bioactivity furnishes spatial and temporal control, and offers the possibility of precision dosing and orthogonal communication with different biomolecules. These inherent attributes of light have been advocated as advantageous for the delivery and/or activation of drugs at diseased sites for a variety of indications. However, the tissue penetrance of light is profoundly wavelength-dependent. Only recently have phototherapeutics that are photoresponsive in the optical window of tissue (600-900 nm) been described. This Review highlights these recent discoveries, along with their limitations and clinical opportunities. In addition, we describe preliminary in vivo studies of prospective phototherapeutics, with an emphasis on the path that remains to be navigated in order to translate light-activated drugs into clinically useful therapeutics. Finally, the unique attributes of phototherapeutics is highlighted by discussing several potential disease applications.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1038/s41570-021-00326-w

Publication Info

Vickerman, Brianna M, Emilia M Zywot, Teresa K Tarrant and David S Lawrence (2021). Taking phototherapeutics from concept to clinical launch. Nature reviews. Chemistry, 5(11). pp. 816–834. 10.1038/s41570-021-00326-w Retrieved from https://hdl.handle.net/10161/25638.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Tarrant

Teresa Kathleen Tarrant

Associate Professor of Medicine

I first became interested in clinical immunology as a medical student studying autoimmune inflammatory eye disease at the National Institutes of Health.  Since then, I have been inspired to understand what causes autoimmunity and immune deficiency disorders in order to improve the quality of life for my patients.  I see patients with multiple complex immune disorders with particular expertise in autoimmune and Rheumatoid arthritis, primary Sjogren's syndrome, and the immunodeficiency disorders Common Variable Immunodeficiency (CVID), Adenosine Deaminase Deficiency (ADA) disorders, and WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis). My research investigates immune targets that may impact either the development of immune disease or identify new therapies for patients.  The goal is to help us understand why and how immunologic diseases develop so that we may better treat them.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.